Calithera Biosciences (NASDAQ:CALA) Earns Hold Rating from Analysts at StockNews.com

Posted by on May 14th, 2025

StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Free Report) in a report issued on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Calithera Biosciences Price Performance

Shares of NASDAQ:CALA opened at $0.00 on Friday. Calithera Biosciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.12.

About Calithera Biosciences

(Get Free Report)

Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.

Read More

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.